Amgen Canada Inc.
| Specific Topics of Lobbying Communications | Intended Outcomes | Associated Subject Matters |
|---|---|---|
|
Communicating with government officials, in general, about the pharmaceutical sector in British Columbia. The goal of these communications is (i) to keep the provincial government informed of general industry developments, initiatives and trends and (ii) to explore potential collaboration, in general, between industry and the provincial government.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health, Science and Technology
|
|
Communicating with government officials about improvements to approval processes for pharmaceuticals, including (i) streamlining rare disease drug review processes and (ii) harmonizing clinical trials and research ethics reviews.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Communicating with government officials about international trade, more specifically trade in the biopharmaceutical sector, including the impact of recent trade-related decisions by the United States of America on the biopharmaceutical sector in Canada.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health, International Trade
|
|
Communicating with government officials about pharmaceutical drug coverage for Indigenous peoples.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health, Indigenous Relations and Reconciliation
|
|
Communicating with government officials about policies and programs designed to support innovative research and development in the pharmaceutical sector.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Communicating with government officials about the federal government's proposed national universal pharmacare program, including the bulk purchase of pharmaceuticals.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Communicating with government officials about the Government of British Columbia's "Life Sciences and Biomanufacturing Strategy".
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health, Science and Technology
|
|
Communicating with government officials about the Government of British Columbia's "Pharmaceutical Care Management Strategy".
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Communicating with government officials about the listing of Amgen's products for reimbursement purposes on government formularies, including on the BC PharmaCare Formulary.
|
Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity, Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|